Blueprint Medicines Announces Submission of New Drug Application to FDA for Pralsetinib for the Treatment of Advanced RET Mutant and RET Fusion-Positive Thyroid Cancers
CAMBRIDGE, Mass., July 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Immunotherapy | New Drug Applications | Rare Diseases | Thyroid | Thyroid Cancer